Chronic inflammatory demyelinating polyradiculoneuropathy: From bench to bedside

Seminars in Neurology

Volumn 32, Issue 3, 2012, Pages 187-195

  Peltier, Amanda C ^a   Donofrio, Peter D ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

CIDP; demyelination; inflammatory neuropathy

Indexed keywords

ALEMTUZUMAB; ALPHA2A INTERFERON; AZATHIOPRINE; BETA1A INTERFERON; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DEXAMETHASONE; IMMUNOGLOBULIN; INTERLEUKIN 2; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PERIPHERAL MYELIN PROTEIN 22; PLACEBO; PREDNISOLONE; PREDNISONE; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA;

ANEMIA; ARTICLE; AUTOIMMUNE DISEASE; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; CEREBROSPINAL FLUID ANALYSIS; CORTICOSTEROID THERAPY; DERMATOMYOSITIS; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SAFETY; ELECTRODIAGNOSIS; HAIR LOSS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LOW DRUG DOSE; NAUSEA; NEUROPATHY; NONHUMAN; PATHOGENESIS; PLASMAPHERESIS; PNEUMONIA; POEMS SYNDROME; POLYMYOSITIS; POLYRADICULONEUROPATHY; PRIORITY JOURNAL; SEPTICEMIA; TREATMENT RESPONSE; VOMITING;

ADRENAL CORTEX HORMONES; ALBUMINS; ANTI-INFLAMMATORY AGENTS; ELECTRODIAGNOSIS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOSUPPRESSIVE AGENTS; PERIPHERAL NERVES; PLASMA EXCHANGE; POLYRADICULONEUROPATHY, CHRONIC INFLAMMATORY DEMYELINATING; STEM CELL TRANSPLANTATION;

EID: 84868234637     PISSN: 02718235     EISSN: 10989021     Source Type: Journal    
DOI: 10.1055/s-0032-1329194     Document Type: Article

References (124)

1. Dyck P. J., Lais A. C., Ohta M., Bastron J. A., Okazaki H., Groover R. V. Chronic inflammatory polyradiculoneuropathy. Mayo Clin Proc: 1975; 50 11 621 637
2. Burns T. M. Chronic inflammatory demyelinating polyradiculoneuropathy. Arch Neurol: 2004; 61 6 973 975
3. Austin J. H. Recurrent polyneuropathies and their corticosteroid treatment; with five-year observations of a placebo-controlled case treated with corticotrophin, cortisone, and prednisone. Brain: 1958; 81 2 157 192
4. Katz J. S., Saperstein D. S., Gronseth G., Amato A. A., Barohn R. J. Distal acquired demyelinating symmetric neuropathy. Neurology: 2000; 54 3 615 620
5. Lewis R. A., Sumner A. J., Brown M. J., Asbury A. K. Multifocal demyelinating neuropathy with persistent conduction block. Neurology: 1982; 32 9 958 964
6. Oh S. J., Joy J. L., Kuruoglu R. "Chronic sensory demyelinating neuropathyo": chronic inflammatory demyelinating polyneuropathy presenting as a pure sensory neuropathy. J Neurol Neurosurg Psychiatry: 1992; 55 8 677 680
7. Pestronk A., Cornblath D. R., Ilyas A. A., et al. A treatable multifocal motor neuropathy with antibodies to GM1 ganglioside. Ann Neurol: 1988; 24 1 73 78
8. Kelly J. J. Jr. The electrodiagnostic findings in peripheral neuropathy associated with monoclonal gammopathy. Muscle Nerve: 1983; 6 7 504 509
9. Cocito D., Durelli L., Isoardo G. Different clinical, electrophysiological and immunological features of CIDP associated with paraproteinaemia. Acta Neurol Scand: 2003; 108 4 274 280
10. McCombe P. A., Pollard J. D., McLeod J. G. Chronic inflammatory demyelinating polyradiculoneuropathy. A clinical and electrophysiological study of 92 cases. Brain: 1987; 110 Pt 6 1617 1630
11. Gabriel C. M., Hughes R. A., Moore S. E., Smith K. J., Walsh F. S. Induction of experimental autoimmune neuritis with peripheral myelin protein-22. Brain: 1998; 121 Pt 10 1895 1902
12. Hughes R. A., Allen D., Makowska A., Gregson N. A. Pathogenesis of chronic inflammatory demyelinating polyradiculoneuropathy. J Peripher Nerv Syst: 2006; 11 1 30 46
13. Kuwahara M., Suzuki S., Takada K., Kusunoki S. Antibodies to LM1 and LM1-containing ganglioside complexes in Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy. J Neuroimmunol: 2011; 239 1-2 87 90
14. Chi L. J., Xu W. H., Zhang Z. W., Huang H. T., Zhang L. M., Zhou J. Distribution of Th17 cells and Th1 cells in peripheral blood and cerebrospinal fluid in chronic inflammatory demyelinating polyradiculoneuropathy. J Peripher Nerv Syst: 2010; 15 4 345 356
15. Archelos J. J., Mäurer M., Jung S., et al. Inhibition of experimental autoimmune neuritis by an antibody to the lymphocyte function-associated antigen-1. Lab Invest: 1994; 70 5 667 675
16. Kieseier B. C., Tani M., Mahad D., et al. Chemokines and chemokine receptors in inflammatory demyelinating neuropathies: a central role for IP-10. Brain: 2002; 125 Pt 4 823 834
17. Mahad D. J., Howell S. J., Woodroofe M. N. Expression of chemokines in cerebrospinal fluid and serum of patients with chronic inflammatory demyelinating polyneuropathy. J Neurol Neurosurg Psychiatry: 2002; 73 3 320 323
18. Mei F. J., Ishizu T., Murai H., et al. Th1 shift in CIDP versus Th2 shift in vasculitic neuropathy in CSF. J Neurol Sci: 2005; 228 1 75 85
19. Meléndez-Vásquez C., Redford J., Choudhary P. P., et al. Immunological investigation of chronic inflammatory demyelinating polyradiculoneuropathy. J Neuroimmunol: 1997; 73 1-2 124 134
20. Schmidt B., Toyka K. V., Kiefer R., Full J., Hartung H. P., Pollard J. Inflammatory infiltrates in sural nerve biopsies in Guillain-Barre syndrome and chronic inflammatory demyelinating neuropathy. Muscle Nerve: 1996; 19 4 474 487
21. Kiefer R., Dangond F., Mueller M., Toyka K. V., Hafler D. A., Hartung H. P. Enhanced B7 costimulatory molecule expression in inflammatory human sural nerve biopsies. J Neurol Neurosurg Psychiatry: 2000; 69 3 362 368
22. Van Rhijn I., Van den Berg L. H., Bosboom W. M., Otten H. G., Logtenberg T. Expression of accessory molecules for T-cell activation in peripheral nerve of patients with CIDP and vasculitic neuropathy. Brain: 2000; 123 Pt 10 2020 2029
23. Murata K., Dalakas M. C. Expression of the co-stimulatory molecule BB-1, the ligands CTLA-4 and CD28 and their mRNAs in chronic inflammatory demyelinating polyneuropathy. Brain: 2000; 123 Pt 8 1660 1666
24. Zivković S. A., Peltier A. C., Iacob T., Lacomis D. Chronic inflammatory demyelinating polyneuropathy and ventilatory failure: report of seven new cases and review of the literature. Acta Neurol Scand: 2011; 124 1 59 63
25. Figueroa J. J., Dyck P. J., Laughlin R. S., et al. Autonomic dysfunction in chronic inflammatory demyelinating polyradiculoneuropathy. Neurology: 2012; 78 10 702 708
26. Laughlin R. S., Dyck P. J., Melton L. J. III, Leibson C., Ransom J., Dyck P. J. Incidence and prevalence of CIDP and the association of diabetes mellitus. Neurology: 2009; 73 1 39 45
27. Rajabally Y. A., Simpson B. S., Beri S., Bankart J., Gosalakkal J. A. Epidemiologic variability of chronic inflammatory demyelinating polyneuropathy with different diagnostic criteria: study of a UK population. Muscle Nerve: 2009; 39 4 432 438
28. McLeod J. G., Pollard J. D., Macaskill P., Mohamed A., Spring P., Khurana V. Prevalence of chronic inflammatory demyelinating polyneuropathy in New South Wales, Australia. Ann Neurol: 1999; 46 6 910 913
29. Iijima M., Koike H., Hattori N., et al. Refractory Peripheral Neuropathy Study Group of Japan Prevalence and incidence rates of chronic inflammatory demyelinating polyneuropathy in the Japanese population. J Neurol Neurosurg Psychiatry: 2008; 79 9 1040 1043
30. Lunn M. P., Manji H., Choudhary P. P., Hughes R. A., Thomas P. K. Chronic inflammatory demyelinating polyradiculoneuropathy: a prevalence study in south east England. J Neurol Neurosurg Psychiatry: 1999; 66 5 677 680
31. Simpson D. M., Olney R. K. Peripheral neuropathies associated with human immunodeficiency virus infection. Neurol Clin: 1992; 10 3 685 711
32. Brannagan T. H. III, Zhou Y. HIV-associated Guillain-Barré syndrome. J Neurol Sci: 2003; 208 1-2 39 42
33. Simmons Z., Albers J. W., Bromberg M. B., Feldman E. L. Long-term follow-up of patients with chronic inflammatory demyelinating polyradiculoneuropathy, without and with monoclonal gammopathy. Brain: 1995; 118 Pt 2 359 368
34. Tackenberg B., Lünemann J. D., Steinbrecher A., et al. Classifications and treatment responses in chronic immune-mediated demyelinating polyneuropathy. Neurology: 2007; 68 19 1622 1629
35. Wadwekar V., Kalita J., Misra U. K. Does the chronic inflammatory demyelinating polyradiculoneuropathy due to secondary cause differ from primary? Neurol India: 2011; 59 5 664 668
36. Larue S., Bombelli F., Viala K., et al. Non-anti-MAG DADS neuropathy as a variant of CIDP: clinical, electrophysiological, laboratory features and response to treatment in 10 cases. Eur J Neurol: 2011; 18 6 899 905
37. Mygland A., Monstad P. Chronic acquired demyelinating symmetric polyneuropathy classified by pattern of weakness. Arch Neurol: 2003; 60 2 260 264
38. Mendell J. R., Kolkin S., Kissel J. T., Weiss K. L., Chakeres D. W., Rammohan K. W. Evidence for central nervous system demyelination in chronic inflammatory demyelinating polyradiculoneuropathy. Neurology: 1987; 37 8 1291 1294
39. Gigli G. L., Carlesimo A., Valente M., et al. Evoked potentials suggest cranial nerves and CNS involvement in chronic relapsing polyradiculoneuropathy. Eur Neurol: 1989; 29 3 145 149
40. Ohtake T., Komori T., Hirose K., Tanabe H. CNS involvement in Japanese patients with chronic inflammatory demyelinating polyradiculoneuropathy. Acta Neurol Scand: 1990; 81 2 108 112
41. Uncini A., Gallucci M., Lugaresi A., Porrini A. M., Onofrj M., Gambi D. CNS involvement in chronic inflammatory demyelinating polyneuropathy: an electrophysiological and MRI study. Electromyogr Clin Neurophysiol: 1991; 31 6 365 371
42. Berger A. R., Herskovitz S., Kaplan J. Late motor involvement in cases presenting as "chronic sensory demyelinating polyneuropathyo" Muscle Nerve: 1995; 18 4 440 444
43. Sinnreich M., Klein C. J., Daube J. R., Engelstad J., Spinner R. J., Dyck P. J. Chronic immune sensory polyradiculopathy: a possibly treatable sensory ataxia. Neurology: 2004; 63 9 1662 1669
44. Larue S., Bombelli F., Viala K., et al. Non-anti-MAG DADS neuropathy as a variant of CIDP: clinical, electrophysiological, laboratory features and response to treatment in 10 cases. Eur J Neurol: 2011; 18 6 899 905
45. Remiche G., Kentos A., Mavroudakis N. Distal acquired demyelinating symmetric neuropathy associated with anti-GM1 antibodies: is this a CIDP variant? Acta Neurol Belg: 2010; 110 1 103 106
46. Sander H. W., Latov N. Research criteria for defining patients with CIDP. Neurology: 2003; 60 8 03 S8 S15
47. Hughes R., Bensa S., Willison H., et al. Inflammatory Neuropathy Cause and Treatment (INCAT) Group Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol: 2001; 50 2 195 201
48. Research criteria for diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP). Report from an Ad Hoc Subcommittee of the American Academy of Neurology AIDS Task Force. Neurology: 1991; 41 5 617 618
49. Bromberg M. B. Review of the evolution of electrodiagnostic criteria for chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve: 2011; 43 6 780 794
50. Albers J. W., Donofrio P. D., McGonagle T. K. Sequential electrodiagnostic abnormalities in acute inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve: 1985; 8 6 528 539
51. Albers J. W., Kelly J. J. Jr. Acquired inflammatory demyelinating polyneuropathies: clinical and electrodiagnostic features. Muscle Nerve: 1989; 12 6 435 451
52. Sander H. W., Latov N. Research criteria for defining patients with CIDP. Neurology: 2003; 60 8 03 S8 S15
53. Nicolas G., Maisonobe T., Le Forestier N., Léger J. M., Bouche P. Proposed revised electrophysiological criteria for chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve: 2002; 25 1 26 30
54. Haq R. U., Fries T. J., Pendlebury W. W., Kenny M. J., Badger G. J., Tandan R. Chronic inflammatory demyelinating polyradiculoneuropathy: a study of proposed electrodiagnostic and histologic criteria. Arch Neurol: 2000; 57 12 1745 1750
55. Thaisetthawatkul P., Logigian E. L., Herrmann D. N. Dispersion of the distal compound muscle action potential as a diagnostic criterion for chronic inflammatory demyelinating polyneuropathy. Neurology: 2002; 59 10 1526 1532
56. Saperstein D. S., Katz J. S., Amato A. A., Barohn R. J. Clinical spectrum of chronic acquired demyelinating polyneuropathies. Muscle Nerve: 2001; 24 3 311 324
57. Nicolas G., Maisonobe T., Le Forestier N., Léger J. M., Bouche P. Proposed revised electrophysiological criteria for chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve: 2002; 25 1 26 30
58. Wilson J., Chawla J., Fisher M. Sensitivity and specificity of electrodiagnostic criteria for CIDP using ROC curves: comparison to patients with diabetic and MGUS associated neuropathies. J Neurol Sci: 2005; 231 1-2 19 28
59. Wilson J. R., Park Y., Fisher M. A. Electrodiagnostic criteria in CIDP: comparison with diabetic neuropathy. Electromyogr Clin Neurophysiol: 2000; 40 3 181 185
60. Latov N. Diagnosis of CIDP. Neurology: 2002; 59 1 2 06 S2 S6
61. Barohn R. J., Kissel J. T., Warmolts J. R., Mendell J. R. Chronic inflammatory demyelinating polyradiculoneuropathy. Clinical characteristics, course, and recommendations for diagnostic criteria. Arch Neurol: 1989; 46 8 878 884
62. Hattori N., Misu K., Koike H., et al. Age of onset influences clinical features of chronic inflammatory demyelinating polyneuropathy. J Neurol Sci: 2001; 184 1 57 63
63. Hahn A. F., Hartung H., Dyck P. J. Chronic inflammatory demyelinating polyradiculoneuropathy. In: Dyck P. J., Thomas P. K., eds. Peripheral Neuropathy. 4th ed. Philadelphia Elsevier Saunders: 2005; 2221 2253
64. Chimowitz M. I., Audet A. M., Hallet A., Kelly J. J. Jr. HIV-associated CIDP. Muscle Nerve: 1989; 12 8 695 696
65. Nobile-Orazio E. Multifocal motor neuropathy. J Neuroimmunol: 2001; 115 1-2 4 18
66. Kalita J., Misra U. K., Yadav R. K. A comparative study of chronic inflammatory demyelinating polyradiculoneuropathy with and without diabetes mellitus. Eur J Neurol: 2007; 14 6 638 643
67. Sommer C., Toyka K. Nerve biopsy in chronic inflammatory neuropathies: in situ biomarkers. J Peripher Nerv Syst: 2011; 16 01 24 29
68. Schmidt B., Toyka K. V., Kiefer R., Full J., Hartung H. P., Pollard J. Inflammatory infiltrates in sural nerve biopsies in Guillain-Barre syndrome and chronic inflammatory demyelinating neuropathy. Muscle Nerve: 1996; 19 4 474 487
69. Sommer C., Koch S., Lammens M., Gabreels-Festen A., Stoll G., Toyka K. V. Macrophage clustering as a diagnostic marker in sural nerve biopsies of patients with CIDP. Neurology: 2005; 65 12 1924 1929
70. Bromberg M. B., Albers J. W. Patterns of sensory nerve conduction abnormalities in demyelinating and axonal peripheral nerve disorders. Muscle Nerve: 1993; 16 3 262 266
71. Saporta M. A., Katona I., Lewis R. A., Masse S., Shy M. E., Li J. Shortened internodal length of dermal myelinated nerve fibres in Charcot-Marie-Tooth disease type 1A. Brain: 2009; 132 Pt 12 3263 3273
72. Taylor B. V., Dyck P. J., Engelstad J., Gruener G., Grant I., Dyck P. J. Multifocal motor neuropathy: pathologic alterations at the site of conduction block. J Neuropathol Exp Neurol: 2004; 63 2 129 137
73. Dalakas M. C. Medscape Advances in the diagnosis, pathogenesis and treatment of CIDP. Nat Rev Neurol: 2011; 7 9 507 517
74. Dyck P. J., O'Brien P. C., Oviatt K. F., et al. Prednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treatment. Ann Neurol: 1982; 11 2 136 141
75. Dalakas M. C., Engel W. K. Chronic relapsing (dysimmune) polyneuropathy: pathogenesis and treatment. Ann Neurol: 1981; 9 Suppl 134 145
76. van Schaik I. N., Eftimov F., van Doorn P. A., et al. van S. Pulsed high-dose dexamethasone versus standard prednisolone treatment for chronic inflammatory demyelinating polyradiculoneuropathy (PREDICT study): a double-blind, randomised, controlled trial. Lancet Neurol: 2010; 9 3 245 253
77. Eftimov F., Vermeulen M., van Doorn P. A., Brusse E., van Schaik I. N. PREDICT Long-term remission of CIDP after pulsed dexamethasone or short-term prednisolone treatment. Neurology: 2012; 78 14 1079 1084
78. Mendell J. R., Barohn R. J., Freimer M. L., et al. Working Group on Peripheral Neuropathy Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy. Neurology: 2001; 56 4 445 449
79. Hughes R. A., Donofrio P., Bril V., et al. ICE Study Group Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurol: 2008; 7 2 136 144
80. Donofrio P. D., Bril V., Dalakas M. C., et al. IGIV-C CIDP Efficacy (ICE) Study Group Safety and tolerability of immune globulin intravenous in chronic inflammatory demyelinating polyradiculoneuropathy. Arch Neurol: 2010; 67 9 1082 1088
81. Eftimov F., Winer J. B., Vermeulen M., de Haan R., van Schaik I. N. Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev: 2009; 1 CD001797
82. Iijima M., Koike H., Sobue G. [Efficacy and availability of intravenous immunoglobulin in chronic inflammatory demyelinating polyneuropathy]. Nihon Rinsho: 2012; 70 4 715 721
83. Cocito D., Serra G., Falcone Y., Paolasso I. The efficacy of subcutaneous immunoglobulin administration in chronic inflammatory demyelinating polyneuropathy responders to intravenous immunoglobulin. J Peripher Nerv Syst: 2011; 16 2 150 152
84. Plasmapheresis and acute Guillain-Barré syndrome. The Guillain-Barré syndrome Study Group. Neurology: 1985; 35 8 1096 1104
85. Dyck P. J., Daube J., O'Brien P., et al. Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy. N Engl J Med: 1986; 314 8 461 465
86. Hahn A. F., Bolton C. F., Pillay N., et al. Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy. A double-blind, sham-controlled, cross-over study. Brain: 1996; 119 Pt 4 1055 1066
87. Mehndiratta M. M., Hughes R. A., Agarwal P. Plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev: 2004; 3 CD003906
88. Galldiks N., Burghaus L., Dohmen C., et al. Immunoadsorption in patients with chronic inflammatory demyelinating polyradiculoneuropathy with unsatisfactory response to first-line treatment. Eur Neurol: 2011; 66 4 183 189
89. Dyck P. J., Litchy W. J., Kratz K. M., et al. A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol: 1994; 36 6 838 845
90. Gorson K. C., Allam G., Ropper A. H. Chronic inflammatory demyelinating polyneuropathy: clinical features and response to treatment in 67 consecutive patients with and without a monoclonal gammopathy. Neurology: 1997; 48 2 321 328
91. Cocito D., Paolasso I., Antonini G., et al. Italian Network for CIDP Register A nationwide retrospective analysis on the effect of immune therapies in patients with chronic inflammatory demyelinating polyradiculoneuropathy. Eur J Neurol: 2010; 17 2 289 294
92. Dyck P. J., O'Brien P., Swanson C., Low P., Daube J. Combined azathioprine and prednisone in chronic inflammatory-demyelinating polyneuropathy. Neurology: 1985; 35 8 1173 1176
93. Good J. L., Chehrenama M., Mayer R. F., Koski C. L. Pulse cyclophosphamide therapy in chronic inflammatory demyelinating polyneuropathy. Neurology: 1998; 51 6 1735 1738
94. Brannagan T. H. III, Pradhan A., Heiman-Patterson T., et al. High-dose cyclophosphamide without stem-cell rescue for refractory CIDP. Neurology: 2002; 58 12 1856 1858
95. Barnett M. H., Pollard J. D., Davies L., McLeod J. G. Cyclosporin A in resistant chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve: 1998; 21 4 454 460
96. Mahattanakul W., Crawford T. O., Griffin J. W., Goldstein J. M., Cornblath D. R. Treatment of chronic inflammatory demyelinating polyneuropathy with cyclosporin-A. J Neurol Neurosurg Psychiatry: 1996; 60 2 185 187
97. Takeuchi A., Shirai S., Horiuchi K., et al. [Successful cyclosporine treatment in 2 patients with refractory CIDP, involving monitoring of both AUC(0-4h) and trough levels]. Rinsho Shinkeigaku: 2012; 52 3 172 177
98. Visudtibhan A., Chiemchanya S., Visudhiphan P. Cyclosporine in chronic inflammatory demyelinating polyradiculoneuropathy. Pediatr Neurol: 2005; 33 5 368 372
99. Chaudhry V., Cornblath D. R., Griffin J. W., O'Brien R., Drachman D. B. Mycophenolate mofetil: a safe and promising immunosuppressant in neuromuscular diseases. Neurology: 2001; 56 1 94 96
100. Mowzoon N., Sussman A., Bradley W. G. Mycophenolate (CellCept) treatment of myasthenia gravis, chronic inflammatory polyneuropathy and inclusion body myositis. J Neurol Sci: 2001; 185 2 119 122
101. Gorson K. C., Amato A. A., Ropper A. H. Efficacy of mycophenolate mofetil in patients with chronic immune demyelinating polyneuropathy. Neurology: 2004; 63 4 715 717
102. Umapathi T., Hughes R. Mycophenolate in treatment-resistant inflammatory neuropathies. Eur J Neurol: 2002; 9 6 683 685
103. RMC Trial Group Randomised controlled trial of methotrexate for chronic inflammatory demyelinating polyradiculoneuropathy (RMC trial): a pilot, multicentre study. Lancet Neurol: 2009; 8 2 158 164
104. Benedetti L., Briani C., Franciotta D., et al. Rituximab in patients with chronic inflammatory demyelinating polyradiculoneuropathy: a report of 13 cases and review of the literature. J Neurol Neurosurg Psychiatry: 2011; 82 3 306 308
105. Gorson K. C., Natarajan N., Ropper A. H., Weinstein R. Rituximab treatment in patients with IVIg-dependent immune polyneuropathy: a prospective pilot trial. Muscle Nerve: 2007; 35 1 66 69
106. Benedetti L., Franciotta D., Beronio A., et al. Rituximab efficacy in CIDP associated with idiopathic thrombocytopenic purpura. Muscle Nerve: 2008; 38 2 1076 1077
107. Sanz P. G., García Méndez C. V., Cueto A. L., et al. Chronic inflammatory demyelinating polyradiculoneuropathy in a patient with systemic lupus erythematosus and good outcome with rituximab treatment. Rheumatol Int: 2011;; Epub ahead of print
108. D'Amico A., Catteruccia M., De Benedetti F., et al. Rituximab in a childhood-onset idiopathic refractory chronic inflammatory demyelinating polyneuropathy. Eur J Paediatr Neurol: 2012; 16 3 301 303
109. Brannagan T. H. III, Patterson S. K. Alemtuzumab: the future of chronic inflammatory demyelinating polyradiculoneuropathy treatment? Expert Rev Clin Immunol: 2010; 6 3 319 321
110. Marsh E. A., Hirst C. L., Llewelyn J. G., et al. Alemtuzumab in the treatment of IVIG-dependent chronic inflammatory demyelinating polyneuropathy. J Neurol: 2010; 257 6 913 919
111. Sabatelli M., Mignogna T., Lippi G., et al. Interferon-alpha may benefit steroid unresponsive chronic inflammatory demyelinating polyneuropathy. J Neurol Neurosurg Psychiatry: 1995; 58 5 638 639
112. Gorson K. C., Ropper A. H., Clark B. D., Dew R. B. III, Simovic D., Allam G. Treatment of chronic inflammatory demyelinating polyneuropathy with interferon-alpha 2a. Neurology: 1998; 50 1 84 87
113. Choudhary P. P., Thompson N., Hughes R. A. Improvement following interferon beta in chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol: 1995; 242 4 252 253
114. Vallat J. M., Hahn A. F., Léger J. M., et al. Interferon beta-1a as an investigational treatment for CIDP. Neurology: 2003; 60 8 03 S23 S28
115. Villa A. M., Garcea O., Di Egidio M., Saizar R., Sica R. E. Interferon beta-1a in chronic inflammatory demyelinating polyneuropathy: case report. Arq Neuropsiquiatr: 2004; 62 3B 892 894
116. Hadden R. D., Sharrack B., Bensa S., Soudain S. E., Hughes R. A. Randomized trial of interferon beta-1a in chronic inflammatory demyelinating polyradiculoneuropathy. Neurology: 1999; 53 1 57 61
117. Kuntzer T., Radziwill A. J., Lettry-Trouillat R., et al. Interferon-beta1a in chronic inflammatory demyelinating polyneuropathy. Neurology: 1999; 53 6 1364 1365
118. Hughes R. A., Gorson K. C., Cros D., et al. Avonex CIDP Study Group Intramuscular interferon beta-1a in chronic inflammatory demyelinating polyradiculoneuropathy. Neurology: 2010; 74 8 651 657
119. Cocito D., Grimaldi S., Paolasso I., et al. Italian Network for CIDP Register Immunosuppressive treatment in refractory chronic inflammatory demyelinating polyradiculoneuropathy. A nationwide retrospective analysis. Eur J Neurol: 2011; 18 12 1417 1421
120. Hughes R. A., Swan A. V., van Doorn P. A. Cytotoxic drugs and interferons for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev: 2004; 4 CD003280
121. Mahdi-Rogers M., Kazmi M., Ferner R., et al. Autologous peripheral blood stem cell transplantation for chronic acquired demyelinating neuropathy. J Peripher Nerv Syst: 2009; 14 2 118 124
122. Brannagan T. H. III. Current diagnosis of CIDP: the need for biomarkers. J Peripher Nerv Syst: 2011; 16 01 3 13
123. Latov N. Biomarkers of CIDP in patients with diabetes or CMT1. J Peripher Nerv Syst: 2011; 16 01 14 17
124. Willison H. J. Biomarkers in experimental models of antibody-mediated neuropathies. J Peripher Nerv Syst: 2011; 16 01 60 62